Premium
Allogeneic transplantation for Hodgkin’s lymphoma
Author(s) -
Corradini Paolo,
Sarina Barbara,
Farina Lucia
Publication year - 2011
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08492.x
Subject(s) - medicine , transplantation , lymphoma , salvage therapy , refractory (planetary science) , surgery , disease , oncology , brentuximab vedotin , radiation therapy , donor lymphocyte infusion , hodgkin lymphoma , graft versus host disease , chemotherapy , physics , astrobiology
Summary Hodgkin’s lymphoma (HL) can be cured in most of the patients, but in case of refractory disease or relapse after autologous stem cell transplantation (SCT) the prognosis becomes very poor. In these patients a consensus about the standard approach has not been achieved so far and only allogeneic SCT has shown a long‐term disease control. The postulated graft‐versus‐Hodgkin’s lymphoma is a matter of controversy, but the clinical responses observed after donor lymphocyte infusions may explain the superiority of alloSCT over standard chemo‐radiotherapy. The results of conventional myeloablative alloSCT had a relevant non‐relapse mortality (NRM), discouraging its widespread application as salvage treatment. In the last 10 years, reduced intensity conditioning (RIC) significantly decreased the NRM, widening the application of alloSCT also to heavily pretreated patients. Taking into account all phase II studies, 20–30% of patients receiving RIC alloSCT are disease‐free and probably some of them are cured.